Breast Cancer News
66.7K views | +0 today
 
Scooped by Susan Zager
onto Breast Cancer News
Scoop.it!

Chemotherapy reductions, interruptions more likely in metastatic breast cancer

Chemotherapy reductions, interruptions more likely in metastatic breast cancer | Breast Cancer News | Scoop.it

"Among women with advanced breast cancer, those with distant metastases were more likely to experience chemotherapy dose alterations due to increased symptom burden and interference with daily life, according to study results presented at the 2014 Oncology Nursing Society Annual Congress.

“Changes in chemotherapy protocol such as dose delays, reductions or stoppages can lead to suboptimal treatment of cancer,” the researchers wrote. “Yet, little is known about the relationship of alterations in chemotherapy and symptom severity and interference with daily life. Clinicians need to understand specific aspects of symptoms, as well as which symptoms may hinder dose completion, so they can provide focused symptom management interventions.”

Researchers reviewed data from 385 women with advanced breast cancer enrolled in a randomized clinical trial to assess these factors associated with chemotherapy dose alterations. Data were collected at baseline, 5 weeks and 11 weeks.

Susan Zager's insight:

To see more information about the 2014 Oncology Nursing Society Annual Congress where the study findings were presented May 1-4, 2014 go to: http://congress.ons.org/wp/wp-content/uploads/2013/10/Saturday.pdf


more...
No comment yet.
Breast Cancer News
Latest News, Research,  Articles of Interest, and Blog Posts
Curated by Susan Zager
Your new post is loading...
Scooped by Susan Zager
Scoop.it!

The sobering thing doctors do when they die

The sobering thing doctors do when they die | Breast Cancer News | Scoop.it
Doctors do the opposite of what they say want to do when they die
Susan Zager's insight:
Fascinating look at doctors and patients choices when dying. It's interesting that the article notes that Doctors usually choose less treatment and longer time in hospice. There is so much pressure to keep doing aggressive drugs that sometimes cause more progression and other side effects that end up being more harmful. Very thought provoking.
To see the original study go to: http://onlinelibrary.wiley.com/doi/10.1111/jgs.14112/abstract
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New technology helps ID aggressive early breast cancer

New technology helps ID aggressive early breast cancer | Breast Cancer News | Scoop.it
Researchers at the University of Michigan developed a new technology that can identify aggressive forms of ductal carcinoma in situ, or stage 0 breast cancer, from non-aggressive varieties.
Susan Zager's insight:

This technology will take time but it's the most no-aggressive way to go.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Cancer, bankruptcy and death: study finds a link

Cancer, bankruptcy and death: study finds a link | Breast Cancer News | Scoop.it
A new study conducted by Fred Hutch's HICOR group has found that the 3 percent of cancer patients who go bankrupt are more likely to die. We talk to study author Dr. Scott Ramsey.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

We’re spending $107 billion on cancer drugs, but is it worth it?

We’re spending $107 billion on cancer drugs, but is it worth it? | Breast Cancer News | Scoop.it
The wave of new cancer treatments may not lengthen patients' lives much.
Susan Zager's insight:

The cost of cancer drugs is growing and expensive. Carolyn Johnson takes an important look on where money is spent and what is getting results as well as where the problems are.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

What You Need to Know About the World's Biggest Cancer Conference

What You Need to Know About the World's Biggest Cancer Conference | Breast Cancer News | Scoop.it
Doctors and biopharma giants will congregate in Chicago on Friday for ASCO's annual meeting, the biggest cancer conference in the business.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Fighting to tame metastatic breast cancer

Fighting to tame metastatic breast cancer | Breast Cancer News | Scoop.it
As sleety rain kept falling, the activists anguished about whether to go ahead with plans to lie on the ground on a recent Saturday evening. Their "die-in" was intended to symbolize the fact that,
Susan Zager's insight:
Proud to be a part of this DieIn. Great article about many people working to get funding for so many #dyingforacure
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer

Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer | Breast Cancer News | Scoop.it
Pictilisib for Estrogen Receptor–Positive, Aromatase Inhibitor–Resistant, Advanced or Metastatic Breast Cancer
Susan Zager's insight:

You made need to sign in for the article, but it's worth it. To see the original study go to: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00106-6/abstract?cc=y=

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Prospects in the Management of Breast Cancer

Prospects in the Management of Breast Cancer | Breast Cancer News | Scoop.it
The panelists, Adam M. Brufsky, MD; Sara A. Hurvitz, MD; Joyce A. O’Shaughnessy, MD; Hope S. Rugo, MD; and Christy A. Russell, MD, share final thoughts on future improvements in the management of breast cancer.
Susan Zager's insight:

Interesting panel discussion including Triple Negative Breast Cancer and MBC

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Beating Cancer: The Real Life Battle for Patients and Their Loved Ones

Beating Cancer: The Real Life Battle for Patients and Their Loved Ones | Breast Cancer News | Scoop.it
Community,news,cure,cure today, cure magazine
Susan Zager's insight:
It's time the real facts of Metastatic breast cancer come out. Great article!
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New strides in metastatic breast cancer research give patients hope

New strides in metastatic breast cancer research give patients hope | Breast Cancer News | Scoop.it
Metastatic breast cancer kills around 40,000 women (and men) a year, but a handful of MBC patients who visited Fred Hutch recently say they're more encouraged than ever. Find out why.
Susan Zager's insight:

Check out this great article and Beth Caldwell's input. It also speaks about the #MBCProject

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

ANGLE device able to track spread of breast cancer

ANGLE device able to track spread of breast cancer | Breast Cancer News | Scoop.it

"The American Association for Cancer Research annual meeting will be told Partsortix performed well in a head-to-head trial with the current method of assessing for cancer spread – painful and invasive surgery to cut out a sliver of affected tissue.

Metastasis is responsible for the vast majority of breast cancer deaths and treatment tends to be based on the biology of the initial tumour biology; however, it is known the cancer changes characteristics as it seeds around the body, so guidelines now state that sample tissue is taken from an area where the cancer has spread, so the drug regimen can be altered.

Susan Zager's insight:

Looking forward to more information coming out of @AACR16

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

#Cancer: Researchers Are Conducting Huge Studies Using Twitter, Facebook

#Cancer: Researchers Are Conducting Huge Studies Using Twitter, Facebook | Breast Cancer News | Scoop.it

"Nearly 40% of men and women will be diagnosed with cancer in their lifetimes, with about 1.7 million of those cases expected in 2016 in the United States (according to the National Cancer Institute). These patients are hoping for better treatments and, hopefully someday, cures. They could also be valuable resources, helping experts develop better therapies, if only staff at research centers like Dana-Farber Cancer Institute in Boston could study their unique cases. Even patients with the same diagnosis, such as breast cancer, have different genetic makeups, both in their healthy cells and in their tumors. These differences provide clues to new genetic factors that may cause the disease, why some patients respond especially well to certain treatments, why some tumors are so resistant to treatment, and how people of different ages or ethnicities are affected.

There's a large community of people, but they are spread out. So Broad Institute/Dana-Farber Integrative Cancer Biology Program in Cambridge, Massachusetts, formed the Metastatic Breast Cancer Project to find a long tail solution: Find people on the Internet. "The traditional way is that when a patient is at [a research] institution, someone will approach them and ask them in person," says Wagle. "We're trying to complement that by doing this 21st century, go directly to patients." That strategy has already netted about 1,700 people (both women and men) with metastatic breast cancer—cancer that has spread beyond the breast, threatening other parts of the body. Wagle says that 95% of them have provided some information about their condition, and that more than 900 have agreed to share medical records, tumor samples, and saliva (for genetic sequencing)."

Susan Zager's insight:

Great article about the incredible work being done at the Broad Institute/Dana Farber Integrative Cancer Biology Project formed to conduct groudbreaking research of Metastatic Breast Cancer by going directly to patients.To learn more go to their web site at:  https://www.mbcproject.org/

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

U.S. CANCER CARE SYSTEM
ILL-EQUIPPED TO DELIVER
NEW ADVANCES TO PATIENTS

U.S. CANCER CARE SYSTEM<br/>ILL-EQUIPPED TO DELIVER<br/>NEW ADVANCES TO PATIENTS | Breast Cancer News | Scoop.it
Susan Zager's insight:

Disturbing cancer care evalutated by @ASCO.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

A Modern, Adaptive FDA Should Support Patients' Right To Try New Medications

A Modern, Adaptive FDA Should Support Patients' Right To Try New Medications | Breast Cancer News | Scoop.it
The agency’s leadership might accomplish what medicine does best: applying science humanely, so that people can get well if it’s possible, and not wait.
Susan Zager's insight:
This article by Elaine Schattner looks at the issues with medications and the FDA approvals when patients need certain meds to stay alive.
Here's some great quotes, while we recommend reading the full article.

Elaine writes:
"A little-cited fact is that many of the 97% cancer patients who aren’t on clinical trials aren’t on study because they don’t qualify for a trial. It’s not that they or their doctors don’t want to participate.
Access to life-saving drugs, within the FDA evaluation system, shouldn’t be based on a patient’s wealth or connections. I’m excited about the FDA’s news, establishing an oncology center related to the Cancer Moonshot. This should expedite the careful and informed evaluation and approval of new drugs, diagnostic tools and medical devices. Ihope the efforother diseases".
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Biden holding cancer summit to pump up support for ‘moonshot’ effort

Biden holding cancer summit to pump up support for ‘moonshot’ effort | Breast Cancer News | Scoop.it
Meetings in Washington and around the country Wednesday will focus on research needs.
Susan Zager's insight:
Check out your local areas and also links to live satellite if you can't travel. From USC go to: http://keckmedia.usc.edu/Mediasite/Catalog/catalogs/Cancer-Moonshot-Summit
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

21st Century Cures Act nears passage with little news media scrutiny

21st Century Cures Act nears passage with little news media scrutiny | Breast Cancer News | Scoop.it
Veteran health care reporter and regular HealthNewsReview.org blogger Trudy Lieberman has been following the 21st Century Cures Act’s journey through Congr
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Despite ASCO Mishap, Data Still Intriguing for Sacituzumab Govitecan in TNBC | Onclive

Despite ASCO Mishap, Data Still Intriguing for Sacituzumab Govitecan in TNBC | Onclive | Breast Cancer News | Scoop.it
Sacituzumab govitecan (IMMU-132) had an objective response rate of 33% in pretreated patients with triple-negative breast cancer, according to updated findings from a phase II study reported by Immunomedics, the manufacturer of the antibody-drug conjugate.
Susan Zager's insight:

This study was excluded from the conference when ASCO became aware that its meeting embargo had been violated when the chairman of Immunomedics reported the results at a conference in April. Meanwhile the author of this article, Jason Broderick, looks at the important findings. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

June 4, 2016: Chicago

June 4, 2016: Chicago | Breast Cancer News | Scoop.it
Right Patient, Right Treatment, Right Now Doctors, Patients, Experts and Advocates Help You Survive the Attacks on YOUR Treatments Join us for our CALL TO ACTION: Right Patient, Right Treatment, Right Now FACTS: The Obstacles to Access CLARITY:...
Susan Zager's insight:
Looks interesting!
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Compassion & Choices | Medical Aid in Dying Act Wins Swift Assembly Committee Vote

Compassion & Choices | Medical Aid in Dying Act Wins Swift Assembly Committee Vote | Breast Cancer News | Scoop.it
Susan Zager's insight:
Hopefully many more states will follow along.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Antibody appears to attack cancer cells, leaving other cells unscathed

Antibody appears to attack cancer cells, leaving other cells unscathed | Breast Cancer News | Scoop.it

"An antibody has been developed from the body's own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit. Cells in the body essentially use a home security system that relies on certain proteins to protect the cell surface and keep it safe. These proteins help the cell avoid injury and even death from unwanted activation of the immune system."

Susan Zager's insight:

To see the study go to: http://www.cell.com/cell-reports/fulltext/S2211-1247(16)30465-X

 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Pembrolizumab Promising in Metastatic Triple-Negative Breast Cancer | Cancer Network

Pembrolizumab Promising in Metastatic Triple-Negative Breast Cancer | Cancer Network | Breast Cancer News | Scoop.it
The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.
Susan Zager's insight:

To see the original study go to: http://jco.ascopubs.org/content/early/2016/04/27/JCO.2015.64.8931.abstract

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

You Pay to Read Research You Fund. That’s Ludicrous

You Pay to Read Research You Fund. That’s Ludicrous | Breast Cancer News | Scoop.it
Saying that Sci-Hub is about copyright infringement is like saying the Boston Tea Party was about late-night vandalism.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

What I Said to the Largest Convening of Cancer Researchers in the Country Yesterday:

What I Said to the Largest Convening of Cancer Researchers in the Country Yesterday: | Breast Cancer News | Scoop.it
Thank you. Thank you very, very much. You’re extremely gracious and generous.
Susan Zager's insight:

Here's a link to @VP Biden speaking about the #moonshot #cancer program. It's very important to stay involved as he spells out the key points in this speech. We must make sure treatment and reserach for Stage IV is part of the molding of this project. This approach can lead to a help real cure for all stages and end deaths from this horrible disease.

This program is for all parties to be involved- so this is not a political statement.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Moffitt Cancer Center Researchers Discover Liver Metastases have Different Radiation Sensitivities Based on Primary Tumor Histology

Moffitt Cancer Center Researchers Discover Liver Metastases have Different Radiation Sensitivities Based on Primary Tumor Histology | Breast Cancer News | Scoop.it

"Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor. 

Previously, Moffitt researchers developed a radiosensitivity index (RSI) that predicts how well tumors respond to radiation therapy based on the expression of 10 different genes. 

“The radiosensitivity index is the most studied and validated radiation specific signature currently available,” said Javier Torres-Roca, M.D., associate member and director of research in Moffitt’s Department of Radiation Oncology. “It is an important step towards gaining a better understanding of radiation sensitivity and developing a personalized approach to radiation treatment.” 

Susan Zager's insight:

To see the original study go to: http://www.redjournal.org/article/S0360-3016%2816%2930040-2/abstract

 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

"State of Cancer Care in America: 2016" Report Finds Unprecedented Opportunity Amid Profound Turbulence

"State of Cancer Care in America: 2016" Report Finds Unprecedented Opportunity Amid Profound Turbulence | Breast Cancer News | Scoop.it
This year’s report clearly shows that strengthening the delivery system for cancer care has to be pursued just as aggressively as its research agenda.
Susan Zager's insight:

There are many problems with the State of Cancer in the USA. This article explains a lot of the report. To see the full report go to: http://jop.ascopubs.org/content/early/2016/03/17/JOP.2015.010462.full.pdf+html

more...
No comment yet.